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Rapid Differential Endogenous Plasminogen Activator
Expression After Acute Middle Cerebral Artery Occlusion
Naohisa Hosomi, MD, PhD; Jacinta Lucero, BS; Ji Hoe Heo, MD, PhD; James A. Koziol, PhD;
Brian R. Copeland, MD; Gregory J. del Zoppo, MD
Background and Purpose—During focal cerebral ischemia, the microvascular matrix (ECM), which participates in
microvascular integrity, is degraded and lost when neurons are injured. Loss of microvascular basal lamina antigens
coincides with rapid expression of select matrix metalloproteinases (MMPs). Plasminogen activators (PAs) may also
play a role in ECM degradation by the generation of plasmin or by MMP activation.
Methods—The endogenous expressions of tissue-type plasminogen activator (tPA), urokinase (uPA), and PA inhibitor-1
(PAI-1) were quantified in 10-mm frozen sections from ischemic and matched nonischemic basal ganglia and in the
plasma of 34 male healthy nonhuman primates before and after middle cerebral artery occlusion (MCA:O).
Results—Within the ischemic basal ganglia, tissue uPA activity and antigen increased significantly within 1 hour after
MCA:O (2P,0.005). tPA activity transiently decreased 2 hours after MCA:O (2P50.01) in concert with an increase
in PAI-1 antigen (2P50.001) but otherwise did not change. The transient decrease in free tPA antigen was marked by
an increase in the tPA–PAI-1 complex (2P,0.001). No significant relations to neuronal injury or intracerebral
hemorrhage were discerned.
Conclusions—The rapid increase in endogenous PA activity is mainly due to significant increases in uPA, but not tPA,
within the ischemic basal ganglia after MCA:O. This increase and an increase in PAI-1 coincided with latent MMP-2
generation and microvascular ECM degeneration but not neuronal injury. (Stroke. 2001;32:1341-1348.)
Key Words: basal ganglia n cerebral ischemia, focal n microcirculation n plasminogen activators
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Focal cerebral ischemia is responsible for a loss of micro-vascular integrity, manifested by increased endothelial
cell permeability and loss of basal lamina matrix antigens.1,2
After experimental middle cerebral artery (MCA) occlusion
(MCA:O) and during reperfusion (MCA:O/R), the major
basal lamina constituents, laminin, collagen IV, and cellular
fibronectin, decrease roughly in parallel,1 in association with
microvascular hemorrhage.2 Loss of basal laminal integrity
coincides with a rapid increase in the expression of latent
matrix metalloproteinase (MMP)-2 in the ischemic core (Ic)
in a nonhuman primate MCA:O model.3 Plasminogen activa-
tors (PAs) may also play several roles in cerebral ischemic
injury to facilitate degradation of basal laminal ligands.
Collagen, laminin, fibronectin, elastin, and/or myelin basic
protein are degraded either directly by plasmin or by select
activated MMPs requiring PA expression.4–8 The disruption
of normal cell-matrix adhesion has been associated with cell
death,9 edema,10 loss of cell viability,11 and hemorrhage3 in
several systems. Latent MMP-9 expression is associated with
hemorrhagic transformation in the nonhuman primate, but the
nature of its activation remains uncertain.3 A contribution of
plasmin, via PA generation, to pro-MMP-9 activation in the
ischemic parenchyma is a potential mechanism. Some or all
of these PA-dependent effects could contribute to central
nervous system (CNS) injury. However, during focal cerebral
ischemia, the tissue-related contributions of PAs to cerebral
vascular and neuronal injury and recovery processes have not
been detailed.
PA activities have been described in the normal rodent
brain.12 Recent reports have indicated that tissue-type PA
(tPA)13 or urokinase (uPA)14 may increase in the rodent brain
after experimental MCA:O. Increased PA activity was de-
tected within the caudate putamen after MCA:O in mice.15
But, there has been considerable disagreement about the
nature of the PA responses to MCA:O in rodents and their
significance. Although uPA activity appears to be increased
in several studies,14,16 there is no agreement concerning the
responses of tPA-like proteinase activity to MCA:O.13,14,16,17
Wang et al13 have suggested that increases in tPA-like
proteinase activity may contribute to excitotoxic neuronal
damage in mice. Therefore, the activation of the PA system
during focal cerebral ischemia requires further scrutiny.
Furthermore, the tissue content of the PAs and their principal
inhibitor must be separated from the contributions of plasma.
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We hypothesized that the upregulation of tissue-related
tPA and/or uPA must occur rapidly to initiate the loss in
microvascular integrity1 and accompany the changes in mi-
crovascular integrin receptor expression18 and neuronal inju-
ry.19 Increased PA expression would suggest a mechanism for
pro-MMP-9 activation, whereas a linear association of in-
creased PA expression with neuronal injury would tie the PA
to neurodegeneration. We demonstrate rapid significant in-
creases in uPA and PA inhibitor (PAI)-1, but not tPA, in the
parenchyma of the ischemic basal ganglia very early after
MCA:O. The sources of these PA-PAI axis components
appear distinctly separate.
Materials and Methods
The experimental procedures used to obtain the tissues for the
present study were approved by the institutional Animal Research
Committee and were performed according to standards published by
the National Research Council (Guide for the Care and Use of
Laboratory Animals) and the US Department of Agriculture Animal
Welfare Act. Every effort was made to ensure that the animals were
free of pain and discomfort. All experiments and procedures were
attended by at least 1 institutional veterinarian, members of the
primate handling staff, research associates, and the principal
investigator.
Experimental Stroke Model
Cerebral tissues from 34 adolescent male baboons (Papio anubis/
cynocephalus) were used for the present study. The procedures for
development of the MCA:O/R stroke model have been detailed in
previous studies.1,3,20 All animals were allowed a 7-day procedure-
free interval after transorbital implantation of an eccentric balloon
compression device around the proximal MCA. Twenty baboons
underwent MCA:O for 1 hour (n54), 2 hours (n56), or 3 hours or
MCA:O with subsequent reperfusion for 1 hour (n54), 4 hours
(n53), or 24 hours (n53). In addition, a group of baboons that did
not undergo device implantation (n56) and a group of baboons with
lenticulostriatal territory injury harvested 7 days later (n56) pro-
vided additional control materials. Two baboons who underwent
only the implantation procedure served as sham-operated controls.
Tissue Processing and Sample Extracts
Experiments were terminated under thiopental Na1 anesthesia by left
ventricular transcardiac perfusion at 180 to 200 mm Hg with chilled
perfusate containing heparin (200 IU/L), nitroprusside (1 mg/L), and
BSA (50 g/L) (Sigma Chemical Co). The perfused brains were
removed en bloc within 15 minutes of complete perfusion and were
subdivided into 1-cm coronal slices. From each slice, symmetrically
located blocks of both basal ganglia were cut and embedded in
Tissue-Tek OCT (Miles Inc). Three consecutive 10-mm cryostat
sections were minced and dissolved in 100 mL lysis buffer
(50 mmol/L Tris-HCl [pH 7.5], 0.1 mol/L L-arginine, 150 mmol/L
NaCl, 1.0% Triton X-100, 0.005% Brij 35, and 0.05% NaN3) for 10
minutes and centrifuged at 4°C for 20 minutes at 9000 rpm.
Supernatants were divided into aliquots and stored at 280°C.
Preliminary experiments determined the optimal conditions for
homogenization and activity extraction.
Blood Sampling
Blood samples were drawn from the peripheral vein into tubes
containing heparin or EDTA at various times and centrifuged at 3000
rpm for 20 minutes, and the plasmas were stored at 280°C.
Protein Concentration
The protein contents of tissue and plasma samples were determined
according to the Bradford method with BSA as the standard. MCA:O
produced a significant reduction in protein content per unit volume
in the ischemic basal ganglia (2P,0.001) (Figure 1), consistent with
previous findings.21 All activity and antigen levels were normalized
for protein content to the Ic (see below). After transcardiac perfusion,
plasma protein (IgG) represented #0.007% of control basal ganglia.
Plasminogen-Gelatin Zymography
Plasminogen-gelatin zymography was performed by a modification
of published methods.3,22 The brain tissue and plasma samples (10
mg protein) were resolved under nonreducing conditions on 8%
SDS-polyacrylamide gels containing 0.01 U/mL plasminogen and
1.5 mg/mL gelatin (Sigma). For standardization, 10 pg of human
melanoma tPA (Sigma) and 10 pg of recombinant human uPA (a
kind gift of Drs Andrew P. Mazar, Attenuon, San Diego, Calif, and
Don Eisenhauer, Abbott Laboratories, Chicago, Ill) were loaded onto
each gel. After electrophoresis, the gels were washed 3 times in 2.5%
Triton X-100 solution and then incubated in 100 mmol/L Tris-HCl
(pH 8.2) buffer for 18 hours at 37°C. The gels were stained with
0.1% amido black solution. On destaining, gelatinolytic activity was
demonstrated as clear zones (Figure 2).
To confirm the nature of each band, plasminogen-containing gels
were incubated with or without 10 mmol/L CaCl2, 0.1 mmol/L
amiloride, 2 mmol/L phenylmethylsulfonyl fluoride (Sigma), or 1
mmol/L trans-epoxysuccinyl-L-leucylamido-butane (E-64, Sigma).
In addition, individual samples were incubated with function-
blocking anti-human polyclonal antibodies against tPA (American
Diagnostica, Inc), uPA (American Diagnostica, Inc), or PAI-1 (a
kind gift of Dr David J. Loskutoff, The Scripps Research Institute,
La Jolla, Calif) for 60 minutes at 37°C before application to the gel.
Immunoblotting
Samples (100 mg protein per lane) were separated under nonreducing
conditions on 8% SDS-polyacrylamide gels and electrophoretically
transferred to nitrocellulose membranes (Schleicher & Schuell Inc)
by the semidry blotting method. Blocking with 5% nonfat milk in
PBS containing 0.1% Tween 20 (PBST) was followed by incubation
with the primary antibody for 1 hour at 37°C and with horseradish
peroxidase-conjugated anti-rabbit or anti-goat IgG antibody (Santa
Cruz Biotechnology Inc or Vector Laboratories, Inc) at 20°C for 1
hour. After each incubation, the blots were washed in PBST to
remove unbound antibody. Bound antibody was detected by en-
hanced chemiluminescence (NEN Life Science Products Inc).
Goat anti-human melanoma tPA antibody (American Diagnostica,
Inc), rabbit anti-human uPA antibody (Dr Andrew P. Mazar, Atten-
uon, San Diego, Calif), and rabbit anti-human PAI-1 antibody (Dr
David J. Loskutoff, The Scripps Research Institute, La Jolla, Calif)
were used as the primary antibodies for the respective immunoblot
studies. Melanoma tPA, recombinant uPA, and recombinant PAI-1
(Dr David J. Loskutoff) served as controls. To prepare the control for
the tPA–PAI-1 and uPA–PAI-1 bound forms, equal amounts of tPA
or uPA and PAI-1 were incubated at 37°C for 10 minutes before
application for electrophoresis. Goat or rabbit nonimmunized IgG
was used as a primary antibody for the control. Absorption studies
were performed by using a primary antibody incubated with mela-
noma tPA or recombinant uPA for 1 hour at 37°C.
Figure 1. Time course of protein content changes in ischemic
and nonischemic basal ganglia after MCA:O.
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Quantification of Immunoblotting
and Zymography
Immunoblot films and zymography gels were scanned by using a
Personal Densitometer SI (Molecular Dynamics Inc) under the mode
of 12 bits per pixel digital resolution and 50-mm pixel size and
quantified by NIH Image 1.61 on a Macintosh platform. Each
measurement was calibrated with a step tablet (Kodak Scanner Step
Tablet, ST-34). The area under the densitometry curve is expressed
as the integrated density (IDA).
Intragel and Intergel Reproducibility
Preliminary plasminogen zymography experiments with human mel-
anoma tPA and recombinant human uPA (from 1 to 1000 pg)
demonstrated that the technique could detect as little as 1 pg of each
Figure 3. Time course of changes in
uPA activity (A) and antigen (B), tPA
activity (C) and antigen (D), and PAI-1
antigen (E) in ischemic and nonischemic
basal ganglia and plasma. At each time
point, uPA activity and antigen and
PAI-1 antigen increased within 1 hour
after MCA:O in the ischemic basal gan-
glia. In contrast, tPA activity, but not
antigen, decreased transiently at 2 hours
after MCA:O.
Figure 2. Representative plasminogen-
gelatin zymograms of the ischemic (R)
and nonischemic (L) basal ganglia dis-
play clear evidence of uPA (54 kDa), tPA
(61 kDa), and tPA–PAI-1 complex (105
kDa) activity. Sample incubation with
respective antibodies (Abs) deleted the
corresponding gelatinolytic band(s) (see
text) (A). Also shown are time-course
studies of PA activities from 3 animals
each: no ischemic challenge (B), 2 hours
after MCA:O (C), and 24-hour reperfu-
sion after 3 hours of MCA:O (D). The
uPA activity band, but not the tPA band,
increased 2 hours after MCA:O.
Hosomi et al Plasminogen Activation and Focal Cerebral Ischemia 1343
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PA. The log (integrated density) for each sample was linear with
respect to the log (PA content) (r50.992 and 2P,0.0001 for tPA,
r50.988 and 2P,0.0001 for uPA). The PA activities from both
brain and plasma samples were all within that range. The intragel
reproducibility for tPA and uPA were quite acceptable, with coeffi-
cients of variability of 2.3% (n58) and 5.4% (n58), respectively, by
use of 10 pg of each PA. The intergel reproducibility of tPA and uPA
was satisfactory, providing coefficients of variability of 11.7% and
11.0%, respectively (n56 gels each).
dUTP Incorporation and Region of Cellular Injury
Evidence of nuclear DNA scission/repair was taken as an indication
of significant cellular injury, as previously described.19 Incorporation
of digoxigenin-dUTP on 10-mm cryosections was detected by the
DNA polymerase I–based procedure. The region containing cells
with nuclear dUTP incorporation (dUTP1) was defined as the Ic. All
activities were normalized for the Ic region. The validity of this
approach was confirmed by immunohistochemistry of adjacent
sections (D.-I. Chang, G.J. del Zoppo, unpublished data, 2001). The
absolute numbers and densities of total dUTP1 cells and dUTP1
neurons were determined within a 1.5-mm2 region of interest
centered within the Ic by computer-assisted quantitative video-
imaging microscopy.
Enzyme-Linked Immunosorbent Assays
tPA, uPA, and PAI-1 antigen contents in brain tissue extract and
plasma were determined by a commercially available ELISA kit
(American Diagnostica Inc). Assays were performed according to
the manufacturer’s instructions. Antigen concentrations were calcu-
lated in nanograms per milligram protein.
Analysis of Data
All data are presented as mean6SD. Differences in the time courses
of molecules between ischemic and matched nonischemic brain
samples were assessed by using 2-way ANOVA, with Bonferroni
corrections for multiple comparisons. One-way ANOVA was used
for comparison between ischemic and nonischemic animals or
between hemorrhagic and nonhemorrhagic animals. Associations
between PA (activity and antigen) and ischemic injury were per-
formed by means of linear regression. Jackknifed standard errors
(SEs) of reported correlation coefficients are provided for assessment
of the precision of the estimated correlations. Significance was set at
2P,0.05.
Results
Zymographic Characterization of uPA, tPA, and
PAI-1 Expression
Plasminogen-gelatin zymographic studies displayed clear ev-
idence of tPA and uPA activity within 10-mm frozen sections
from both ischemic and nonischemic basal ganglia (Figure 2).
Three bands (105, 61, and 54 kDa) were identified in all
plasma-free brain tissue extracts, and 2 bands (105 and 54
kDa) were identified in all plasma samples, which were
inhibited by phenylmethylsulfonyl fluoride but not the cys-
teine protease inhibitor E-64. No proteolytic bands were seen
in the plasminogen-free gel whether or not the incubation
buffer contained CaCl2. These findings confirmed that the
gelatinolytic activities were serine proteases that cleave
plasminogen to plasmin and were not MMPs. Plasmin activ-
ity was not detectable with plasminogen-free zymography.
The 2 proteolytic bands of 61 and 105 kDa were inhibited by
a function-blocking antibody against human tPA. The 105-
kDa band was also inhibited by the anti–PAI-1 antibody,
identifying it with the tPA–PAI-1 complex. The single
proteolytic band of 54 kDa was inhibited by amiloride and by
the function-blocking antibody against human uPA.
uPA Expression During MCA:O
Parenchymal uPA activity and antigen increased significantly
within 1 to 2 hours after MCA:O in the ischemic basal ganglia
(2P,0.005) (Figures 2, 3A, and 3B). Both uPA activity and
antigen were significantly greater in the Ic regions than in
identical nonischemic tissues (2P,0.001) (Figure 4). No
difference in uPA activity or antigen was observed between
the sham-operated and control animals.
In the plasma, uPA activity, but not antigen, demonstrated
a small but significant increase early after MCA:O (2P,0.05)
(Figure 3A and 3B). Plasma uPA antigen content did not
change appreciably over the time from MCA:O.
tPA and PAI-1 Expression During MCA:O
A significant increase in PAI-1 antigen (2P50.001) and a
decrease in free tPA activity (2P50.01) were seen by 2 hours
after MCA:O in the ischemic basal ganglia compared with the
nonischemic regions (Figure 3C and 3E). A transient increase
in the tPA–PAI-1 complex and a coordinate decrease in
unbound tPA at 2 hours after MCA:O (2P,0.001) explained
these changes in the ischemic tissue (Figure 5). Total paren-
Figure 4. Comparison of uPA antigen and activity, tPA antigen
and activity, and PAI-1 antigen between animals with and with-
out ischemic injury. uPA activity and antigen and PAI-1 antigen
were significantly greater in the Ic region of the animals under-
going MCA:O than in those without ischemic injury. Symbols
represent individual animals from each time point. *2P,0.01 vs
nonischemic basal ganglia.
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chymal tPA antigen content remained unchanged throughout
MCA:O/R (Figure 3D), and both tPA antigen and activity in
the Ic region were not different in control and sham-operated
animals (2P50.55) (Figure 4). But PAI-1 antigen in the Ic
region in all ischemic animals increased significantly
(2P,0.003).
In plasma, only the gelatinolytic activity of the tPA–PAI-1
complex was detected. Plasma PAI-1 antigen increased sig-
nificantly (2P,0.05) after MCA:O, in parallel with the
increase in PAI-1 antigen in the ischemic basal ganglia
(Figure 3E).
PA Expression and Neuronal Injury
The relations of uPA activity/antigen, tPA activity/antigen,
and PAI-I antigen content to the density of dUTP1 cells and
neurons at 2-hour MCA:O were examined.3,19 No significant
linear relationship between the contents of each PA or PAI
and the density (number per unit area) of dUTP1 neurons was
observed: uPA activity/antigen5(r50.739, SE50.257,
2P50.093)/(r50.803, SE50.242, 2P50.054); tPA activity/
antigen5(r50.218, SE50.539, 2P50.678)/(r50.286,
SE50.257, 2P50.583); and PAI-1 antigen5(r50.687,
SE50.232, 2P50.132). However, a weak association with
uPA content might exist. This is because of the large SE in
the uPA relationships.
Association of PAs With
Hemorrhagic Transformation
At least 1 animal at each time point, 15 in total (44.1%),
demonstrated visible evidence of hemorrhagic transformation
within the Ic region after MCA:O. No significant differences
in tPA, uPA, and PAI-1 contents between the animals that
displayed hemorrhagic transformation and those without
hemorrhagic transformation after MCA:O were detected
(Figure 6).
Discussion
Plasmin, in addition to dissolving fibrin-containing thrombi
and fibrinogen, is capable of degrading selected matrix
proteins of the basal lamina, elastin, and myelin basic protein
either directly or through the activation of select latent
MMPs.4–8 The ability of PAs to alter microvascular matrix
integrity in response to focal cerebral ischemia has so far not
been clearly defined.13,14,23 The initial step is to examine the
effect of MCA:O on the PA/PAI axis within the brain
parenchyma. From these experiments and those of others,12
Figure 5. Immunoblot study of tPA and PAI-1 antigens in ische-
mic and nonischemic basal ganglia (see Figure 2). Total tPA
antigen remained unchanged, but a significant reduction in free
tPA, equivalent to the formation of detectable tPA–PAI-1 com-
plex, was seen 2 hours after MCA:O in the ischemic basal gan-
glia. L represents the nonischemic basal ganglia. R represents
the ischemic basal ganglia.
Figure 6. Comparison of uPA, tPA, and PAI-1 antigens between
the ischemic animals with or without hemorrhagic transforma-
tion. For uPA and PAI-1, compared with control animals, ani-
mals undergoing MCA:O displayed significantly greater antigen
levels whether they presented hemorrhagic transformation or
not. No difference in tPA antigen levels was observed between
the normal control and MCA:O animals. Symbols represent indi-
vidual animals from each time point. *2P,0.01 vs nonischemic
basal ganglia.
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there appears to be no zymographic evidence of free plasmin
in normal brain tissue. We demonstrate an immediate signif-
icant increase in gelatin-proteolytic activity after MCA:O that
was mainly due to significant increases in uPA within the
ischemic basal ganglia. Parallel increases in PAI-1 were
reflected by an increase in tPA–PAI-1 complex formation and
a transient decrease in tPA activity in the same territory. uPA
antigen and activity and tPA-associated PAI-1 antigen (as-
signed to the Ic region) increased significantly during focal
cerebral ischemia compared with no ischemic injury. How-
ever, no relation to neuronal injury was evident. Furthermore,
there was no significant difference among the animals that
displayed hemorrhagic transformation and those without
hemorrhagic transformation with respect to uPA and
tPA/PAI-1.
The extracellular matrix provides a substructure for the
endothelial cell and astrocyte components of the cerebral
microvasculature, contributing a second element of the blood-
brain barrier. Intact microvascular basal lamina and integrin-
mediated matrix adhesion are required for cell survival.9,11
Focal cerebral ischemia degrades microvascular integrity
through major alterations in endothelial cell permeability and
loss of the vascular matrix.2 The major basal lamina constit-
uents, including laminin-1, laminin-5, collagen IV, and cel-
lular fibronectin, decrease roughly in parallel during MCA:O/
R.1,18 That loss is associated with microvascular hemorrhage.2
From parallel studies, loss of basal laminal integrity and
neuronal injury are accompanied by a rapid simultaneous
increase in tissue expression of uPA and latent MMP-2, but
not tPA, in this model.3,19 PAs may facilitate degradation of
basal lamina via several pathways. Plasmin and uPA, but not
tPA, can activate latent MMP-1, MMP-3, and MMP-9, or in
the case of pro-MMP-2, activation is through the proteolytic
activation of membrane type-1–MMP.4,8,24–26 Some or all of
these PA-dependent effects can contribute to postischemic
CNS injury.
With a modification of zymography with the use of gelatin
(collagen) as the plasmin substrate, tPA and uPA activities
from 10-mm frozen sections were readily detectable and
reproducible. Within nonischemic basal ganglia, tPA activity
(calculated from the normalized integrated densities) was
’67% of uPA activity in control animals, although tPA
antigen content was 33 times that of uPA antigen. When
casein was used as the substrate for zymography, tPA activity
was ’156% of uPA activity in control animals. These
differences may reflect the separate requirements for plasmin
formation by tPA and uPA activity with gelatin as the
substrate, the known contributions of fibrin to optimal in vivo
plasminogen activation by tPA,27 or other aspects of the
activation of plasminogen by tPA. Nonetheless, the simple
extraction procedure used in the present study released nearly
all uPA and tPA antigen/activity into the soluble phase
(96.8%/96.5% and 97.3%/97.4% [n56], respectively). The
specific activities of uPA or tPA were similar in the soluble
and the nonsoluble phases (data not shown). The low tPA
specific activity, compared with uPA specific activity, is not
readily explained by inhibition with PAI-1, because the
tPA–PAI-1 complex levels in nonischemic tissue were low.
Importantly, although the activity assays attempt to detect
matrix-relevant PA activities, the true condition within cere-
bral tissue is unknown.
Rosenberg et al14 first described increased uPA-like and
decreased tPA-like proteinase activities by 12 to 24 hours
after permanent MCA:O in Wistar-Kyoto rats and SHR,
whereas Ahn et al16 noted an increase in uPA-like proteinase
activity and no change in tPA-like proteinase activity in
C57BL/6J mice.16 Wang et al13 suggested that increases in
tPA-like proteinase activity after MCA:O contribute to neu-
rodegeneration. tPA, but not uPA, was assigned a role in
neuronal injury within the murine hippocampus.13,28 The
appearance of both PAs in neuronal cells has been reviewed
recently.29 Pfefferkorn et al15 also observed increased PA
activity within the caudate putamen by 9 hours after MCA:O
in Wistar rats, although the PA was not defined. PAI-1
antigen was apparently increased 4 hours after MCA:O in
Wistar rats,30 but no relation of PAI-1 to uPA and tPA activity
has been reported. The very rapid (1-hour) increase in uPA,
the increase in the tPA–PAI-1 complex, and the transient
decrease in free tPA are consistent findings matching the
rapid appearance of other gene products in the microvascu-
lature after MCA:O in the nonhuman primate.17,31–33 Differ-
ences in the species and models used, ancillary effects of the
anesthetics in the rodent studies, retained plasma, the use of
the more sensitive zymographic assays in the present exper-
iments, and other technical differences may also contribute to
the discrepant findings. In recent studies, we have shown that
residual plasma significantly decreases the activity of tPA
and uPA in rodent brain tissue samples (G.J. del Zoppo, E.
Lo, M. Asahi, S.E. Baer, unpublished data, 2000).19
uPA synthesis has been attributed to a number of CNS cell
types, including endothelial cells, neurons, astrocytes, and
microglia in vivo or in vitro.29,33–36 Given the rapid and
persistent elevation of uPA in the ischemic basal ganglia, it is
unlikely that uPA is derived from the plasma compartment. If
only a contribution of edema to the tissue content of plasma
and stable plasma uPA content are assumed, a mechanism to
concentrate uPA 40-fold from plasma would be required to
explain the early tissue increase in uPA content.
In contrast, the PAI-1 content of ischemic tissue and
plasma increased in parallel, suggesting that plasma PAI-1
entered the edema fluid directly as early as 1 to 2 hours after
MCA:O. Although PAI-1 synthesis has been attributed to
endothelial cells, neurons, and astrocytes,32,37,38 any in situ
production by normal brain tissue might be overwhelmed by
plasma PAI-1. Given the parallel increases in tissue and
plasma PAI-1, it is likely that a common source of the
inhibitor is the endothelium. Increased PAI-1 mRNA and
PAI-1 immunoreactive microvessels have been detected 4
hours after MCA:O in Wistar rats.30 Docagne et al17 observed
that PAI-1, but not tPA, mRNA expression was increased
between 24 hours and 3 days after MCA:O in mice.
In the ischemic basal ganglia, total tPA antigen did not
change, although free tPA activity decreased transiently. The
early decrease in tPA activity is explained by formation of the
tPA–PAI-1 complex. tPA, uPA, and PAI-1 secretion have
been attributed variously to stimulated endothelial cells,
neurons, astrocytes, or microglia in vivo or in vitro,32–38 but
tPA antigen and activity did not accumulate in the ischemic
1346 Stroke June 2001
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tissue in the present study. In the nonischemic brain, tPA
antigen is localized to selected noncapillary microvessels.39
The differential expression of tPA relative to uPA and PAI-1
might be explained by early stimulation of uPA and PAI-1
generation by tumor necrosis factor-a and -b, transforming
growth factor-b, and interleukin-1b (all inflammatory cyto-
kines), which do not stimulate endothelial cell tPA synthesis
and secretion.17,32,33 Expression of these cytokines increases
early within the ischemic zone in rodents after MCA:O.40,41
With human microvascular endothelial cells, epidermal
growth factor increases the synthesis and secretion of tPA,
which is inhibited by tumor necrosis factor-a.42 Therefore,
microvascular endothelium may be responsible for the in-
creased uPA and PAI-1 antigen, but not tPA antigen.
Recent reports have suggested that tPA might promote
neurodegeneration within the rat hippocampus by alteration
in laminin integrity.13,43 However, there was no firm relation
of uPA, tPA, and PAI-I content to neuronal injury in the
ischemic basal ganglia by 2 hours of MCA:O in the present
study. This differs from the significant linear relationship of
pro-MMP-2 content to neuronal injury in the same setting.3
Recent reports comparing uPA(2/2), tPA(2/2), PAI-1(2/2), plas-
minogen (2/2), and wild-type mice suggest that the absence of
tPA, but not uPA, decreased the apparent volume of ischemic
injury.23 Furthermore, plasminogen (2/2) constructs had in-
creased regions of ischemic injury. Those experiments do not
address the acute condition and are subject to other concerns
noted for selected well-characterized knockout and transgenic
mouse preparations subject to MCA:O.23,44–46 Despite the
lack of change in total tPA antigen, it cannot be excluded that
tPA increases in microscopically localized areas and contrib-
utes to neuronal injury.
Although no direct association of uPA with hemorrhagic
transformation was observed in the present study (Figure 6),
increased uPA in the ischemic zones of all animals could
promote the activation of pro-MMP-9, which is associated
with hemorrhagic transformation in this model. At the clinical
level, it seems likely that interventional treatment with
exogenous PAs could further increase the risk of hemorrhagic
transformation if endogenous uPA is already increased. This
argument assumes that the extravasation of blood is not itself
the source of the increased pro-MMP-9.
The significant increase in uPA within the ischemic basal
ganglia coincides with pro-MMP-2 generation and microvas-
cular matrix degeneration, but not neuronal injury, after
MCA:O. Despite the rapid and persistent increase in gelatin-
proteolytic activity mainly due to significantly increased uPA
and the decreased tPA activity 2 hours after MCA:O, the
actual compartmentalization of the endogenous PAs in the
CNS and their individual effects on microvascular matrix,
neuronal integrity, and clinical outcome remain to be defined.
Acknowledgments
This research was supported by grants RO1 NS-26945 and RO1
NS-38710 of the National Institute of Neurological Disorders and
Stroke (Drs del Zoppo and Hosomi) and a fellowship from the
Uehara Memorial Foundation (Dr Hosomi).
References
1. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal
lamina antigens disappear during cerebral ischemia and reperfusion.
Stroke. 1995;26:2120–2126.
2. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and
microvascular integrity during focal cerebral ischemia/reperfusion.
J Cereb Blood Flow Metab. 1996;16:1373–1378.
3. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ.
Matrix metalloproteinases increase very early during experimental focal
cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624–633.
4. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement
membrane type IV collagen degradation: evidence for the involvement of
a proteolytic cascade independent of metalloproteinases. Cancer Res.
1990;50:5997–6001.
5. Norton WT, Cammer W, Bloom BR, Gordon S. Neutral proteinases
secreted by macrophages degrade basic protein: a possible mechanism of
inflammatory demyelination. Adv Exp Med Biol. 1978;100:365–381.
6. McGuire PG, Seeds NW. The interaction of plasminogen activator with a
reconstituted basement membrane matrix and extracellular macromol-
ecules produced by cultured epithelial cells. J Cell Biochem. 1989;40:
215–227.
7. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation
and physiological functions. Annu Rev Cell Biol. 1988;4:93–126.
8. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin
system. J Clin Invest. 1991;88:1067–1072.
9. Frisch SM, Francis H. Disruption of epithelial cell-matrix interaction
induces apoptosis. J Cell Biol. 1994;124:619–626.
10. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in
intracerebral hemorrhage in the rat. Neurology. 1997;48:921–926.
11. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E,
Colotta F. Inhibition of anchorage-dependent cell spreadings triggers
apoptosis in cultured human endothelial cells. J Cell Biol. 1994;127:
537–546.
12. Sappino A-P, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A,
Vassalli J-D. Extracellular proteolysis in the adult murine brain. J Clin
Invest. 1993;92:679–685.
13. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA.
Tissue plasminogen activator (tPA) increases neuronal damage after focal
cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;
4:228–231.
14. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade
enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow
Metab. 1996;16:360–366.
15. Pfefferkorn T, Staufer B, Liebetrau M, Bultemeier G, Vosko MR,
Zimmermann C, Hamann GF. Plasminogen activation in focal cerebral
ischemia and reperfusion. J Cereb Blood Flow Metab. 2000;20:337–342.
16. Ahn MY, Zhang ZG, Tsang W, Chopp M. Endogenous plasminogen
activator expression after embolic focal cerebral ischemia in mice. Brain
Res. 1999;837:169–176.
17. Docagne F, Nicole O, Marti HH, MacKenzie ET, Buisson A, Vivien D.
Transforming growth factor-b1 as a regulator of the serpins/t-PA axis in
cerebral ischemia. FASEB J. 1999;13:1315–1324.
18. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ. Rapid
disruption of an astrocyte interaction with the extracellular matrix
mediated by integrin a6b4 during focal cerebral ischemia/reperfusion.
Stroke. 1997;28:858–865.
19. Tagaya M, Liu K-F, Copeland B, Seiffert D, Engler R, Garcia JH, del
Zoppo GJ. DNA scission after focal brain ischemia: temporal differences
in two species. Stroke. 1997;28:1245–1254.
20. del Zoppo GJ, Copeland BR, Harker LA, Waltz TA, Zyroff J, Hanson SR,
Battenberg E. Experimental acute thrombotic stroke in baboons. Stroke.
1986;17:1254–1265.
21. Bell BA, Symon L, Branston NM. CBF and time thresholds for the
formation of ischemic cerebral edema, and effect of reperfusion in
baboons. J Neurosurg. 1985;62:31–41.
22. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activa-
tors in polyacrylamide gels containing sodium dodecyl sulfate and copo-
lymerized substrate. Anal Biochem. 1980;102:196–202.
23. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plas-
minogen system components in focal cerebral ischemic infarction: a gene
targeting and gene transfer study in mice. Circulation. 1999;99:
2440–2444.
24. Kazes I, Delarue F, Hagege J, Bouzhir-Sima L, Rondeau E, Sraer JD,
Nguyen G. Soluble latent membrane-type 1 matrix metalloprotease
Hosomi et al Plasminogen Activation and Focal Cerebral Ischemia 1347
 at CONS KESLI on August 6, 2014http://stroke.ahajournals.org/Downloaded from 
secreted by human mesangial cells is activated by urokinase. Kidney Int.
1998;54:1976–1984.
25. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ,
Goldberg GI. Tissue cooperation in a proteolytic cascade activating
human interstitial collagenase. Proc Natl Acad Sci U S A. 1989;86:
2632–2636.
26. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S,
Mignatti P. Control of type IV collagenase activity by components of the
urokinase-plasmin system: a regulatory mechanism with cell-bound
reactants. EMBO J. 1997;16:2319–2332.
27. Collen D, Lijnen HR, Bulens F, Vandamme AM, Tulinsky A, Nelles L.
Biochemical and functional characterization of human tissue-type plas-
minogen activator variants with mutagenized kringle domains. J Biol
Chem. 1990;265:12184–12191.
28. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extra-
cellular proteolytic cascade promotes neuronal degeneration in the mouse
hippocampus. J Neurosci. 1997;17:543–552.
29. Vivien D, Buisson A. Serine protease inhibitors: novel therapeutic targets
for stroke? J Cereb Blood Flow Metab. 2000;20:755–764.
30. Zhang GZ, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C,
Ho K-L. Cerebral microvascular obstruction by fibrin is associated with
upregulation of PAI-1 acutely after onset of focal embolic ischemia in
rats. J Neurosci. 1999;19:10898–10907.
31. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland BR, del
Zoppo GJ. Activated microvessels express vascular endothelial growth
factor and integrin avb3 during focal cerebral ischemia. J Cereb Blood
Flow Metab. 1999;19:1038–1050.
32. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ.
Cytokine activation of vascular endothelium: effects on tissue-type plas-
minogen activator and type 1 plasminogen activator inhibitor. J Biol
Chem. 1988;263:5797–5803.
33. van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor
necrosis factor induces the production of urokinase-type plasminogen
activator by human endothelial cells. Blood. 1990;75:1991–1998.
34. Masos T, Miskin R. Localization of urokinase-type plasminogen activator
mRNA in the adult mouse brain. Brain Res Mol Brain Res. 1996;35:
139–148.
35. Tranque P, Naftolin F, Robbins R. Differential regulation of astrocyte
plasminogen activators by insulin-like growth factor-I and epidermal
growth factor. Endocrinology. 1994;134:2606–2613.
36. Nakajima K, Tsuzaki N, Shimojo M, Hamanoue M, Kohsaka S. Microglia
isolated from rat brain secrete a urokinase-type plasminogen activator.
Brain Res. 1992;577:285–292.
37. Patterson PH. On the role of proteases, their inhibitors and the extra-
cellular matrix in promoting neurite outgrowth. J Physiol (Paris). 1985;
80:207–211.
38. Vincent VA, Lowik CW, Verheijen JH, de Bart AC, Tilders FJ, Van Dam
AM. Role of astrocyte-derived tissue-type plasminogen activator in the
regulation of endotoxin-stimulated nitric oxide production by microglial
cells. Glia. 1998;22:130–137.
39. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in
the endothelium of a limited number of vessels. Am J Pathol. 1994;144:
855–861.
40. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC,
Feuerstein GZ. Tumor necrosis factor-a expression in ischemic neurons.
Stroke. 1994;25:1481–1488.
41. Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell
NJ. The progression and topographic distribution of interleukin-1b
expression after permanent middle cerebral artery occlusion in the rat.
J Cereb Blood Flow Metab. 1999;19:87–98.
42. Mawatari M, Okamura K, Matsuda T, Hamanaka R, Mizoguchi H,
Higashio K, Kohno K, Kuwano M. Tumor necrosis factor and epidermal
growth factor modulate migration of human microvascular endothelial
cells and production of tissue-type plasminogen activator and its inhibitor.
Exp Cell Res. 1991;192:574–580.
43. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted
by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917–925.
44. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz
MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice
are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996;16:
981–987.
45. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased
susceptibility to ischemic brain damage in transgenic mice overex-
pressing the amyloid precursor protein. J Neurosci. 1997;17:7655–7661.
46. Maeda K, Hata R, Bader M, Walther T, Hossmann KA. Larger anas-
tomoses in angiotensinogen-knockout mice attenuate early metabolic
disturbances after middle cerebral artery occlusion. J Cereb Blood Flow
Metab. 1999;19:1092–1098.
1348 Stroke June 2001
 at CONS KESLI on August 6, 2014http://stroke.ahajournals.org/Downloaded from 
